CircSMAD3 represses SMAD3 phosphorylation and ameliorates cardiac remodeling by recruiting YBX1

Area of Science:

• Cardiovascular Biology
• Molecular Medicine
• RNA Therapeutics

Background:

• Circular RNAs (circRNAs) are increasingly recognized for their roles in various diseases.
• The transforming growth factor beta (TGFβ) signaling pathway is critical in cardiac remodeling.
• Dysregulation of TGFβ signaling contributes to heart failure pathogenesis.

Purpose of the Study:

• To investigate the role of a novel circRNA in the TGFβ pathway in cardiac remodeling.
• To identify circRNAs as potential therapeutic targets for heart failure.
• To elucidate the mechanism by which circSMAD3 affects cardiac remodeling.

Main Methods:

• Identification of circRNAs in murine heart failure models.
• In vitro studies using cardiomyocyte and cardiac fibroblast cell models.
• Mechanistic studies involving protein-RNA interactions and signaling pathway analysis.

Main Results:

• A circRNA, named circSMAD3, was found to be significantly downregulated in heart failure.
• circSMAD3 administration mitigated cardiomyocyte hypertrophy and cardiac fibroblast activation in vitro.
• circSMAD3 was shown to interact with YBX1, stabilize it, and disrupt the TGFβ/SMAD3 signaling pathway.

Conclusions:

• circSMAD3 plays a protective role against cardiac remodeling.
• circSMAD3 represents a potential novel therapeutic target for heart failure.
• Targeting circSMAD3 may offer a new strategy for treating cardiovascular diseases.